<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Cefixime</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00671</strong>&#160; (APRD00583)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00671/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00671/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00671.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00671.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00671.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00671.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00671.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00671">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Cefixim</td><td>German</td><td>INN</td></tr><tr><td>Cefixima</td><td>Spanish</td><td>INN</td></tr><tr><td>C&#233;fixime</td><td>French</td><td>INN</td></tr><tr><td>Cefiximum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cefixoral</td><td>Menarini</td></tr><tr><td>Cefspan</td><td>GlaxoSmithKline</td></tr><tr><td>Cephoral</td><td>Merck</td></tr><tr><td>Fixam</td><td>Solas</td></tr><tr><td>Fixspor</td><td>Invision</td></tr><tr><td>Hifen</td><td>Hetero</td></tr><tr><td>InfectoOpticef</td><td>Infectopharm</td></tr><tr><td>Kuracef</td><td>Sanofi-Aventis</td></tr><tr><td>Letix</td><td>Adley</td></tr><tr><td>Ofex</td><td>Delta</td></tr><tr><td>Omnatax-O</td><td>Abbott</td></tr><tr><td>Oracef</td><td>Micro Labs</td></tr><tr><td>Oroken</td><td>Sanofi Aventis</td></tr><tr><td>Sancefix</td><td>Sandoz</td></tr><tr><td>Secef</td><td>Novartis</td></tr><tr><td>Supran</td><td>Teva</td></tr><tr><td>Suprax</td><td>Sanofi Aventis</td></tr><tr><td>Suprax 125</td><td>Lupin</td></tr><tr><td>Tricef</td><td>Merck</td></tr><tr><td>Unixime</td><td>Firma</td></tr><tr><td>Uro-Cephoral</td><td>Merck</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Fixx Clav</td><td>Cefixime and Clavulanic Acid</td></tr><tr><td>Starfix-OF</td><td>Cefixime and Ofloxacin</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-bacterial-agents">Anti-Bacterial Agents</a></li>
<li><a href="/mesh/cephalosporins">Cephalosporins</a></li></ul></td></tr><tr><th>CAS number</th><td>79350-37-1</td></tr><tr><th>Weight</th><td>Average: 453.45<br>Monoisotopic: 453.041289239</td></tr><tr><th>Chemical Formula</th><td>C<sub>16</sub>H<sub>15</sub>N<sub>5</sub>O<sub>7</sub>S<sub>2</sub></td></tr><tr><th>InChI Key</th><td>OKBVVJOGVLARMR-QSWIMTSFSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9-/t10-,14-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1)C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Lactams</td></tr><tr><th>Subclass</th><td>Beta Lactams</td></tr><tr><th>Direct parent</th><td>Cephalosporins</td></tr><tr><th>Alternative parents</th><td>N-acyl-alpha Amino Acids and Derivatives; Alpha Amino Acid Amides; 2,4-disubstituted Thiazoles; Primary Aromatic Amines; 1,3-Thiazines; Dicarboxylic Acids and Derivatives; Aminothiazoles; Tertiary Carboxylic Acid Amides; Hemiaminals; Secondary Carboxylic Acid Amides; Oxime Ethers; Polyols; Azetidines; Tertiary Amines; Polyamines; Enamines; Enolates; Aminals; Thioethers; Carboxylic Acids; Imines</td></tr><tr><th>Substituents</th><td>n-acyl-alpha amino acid or derivative; alpha-amino acid amide; alpha-amino acid or derivative; 2,4-disubstituted 1,3-thiazole; dicarboxylic acid derivative; 1,3-thiazolamine; primary aromatic amine; meta-thiazine; azole; thiazole; tertiary carboxylic acid amide; carboxamide group; azetidine; polyol; hemiaminal; secondary carboxylic acid amide; oxime ether; tertiary amine; carboxylic acid; polyamine; aminal; enamine; enolate; thioether; carboxylic acid derivative; amine; primary amine; organonitrogen compound; imine</td></tr><tr><th>Classification description</th><td>This compound belongs to the cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moeity or a derivative thereof.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: (1) uncomplicated urinary tract infections caused by <i>Escherichia coli</i> and <i>Proteus mirabilis</i>, (2) otitis media caused by <i>Haemophilus influenzae</i> (beta-lactamase positive and negative strains), <i>Moraxella catarrhalis</i> (most of which are beta-lactamase positive), and <i>S. pyogenes</i>, (3) pharyngitis and tonsillitis caused by <i>S. pyogenes</i>, (4) acute bronchitis and acute exacerbations of chronic bronchitis caused by <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> (beta-lactamase positive and negative strains), and (5) uncomplicated gonorrhea (cervical/urethral) caused by <i>Neisseria gonorrhoeae</i> (penicillinase- and non-penicillinase-producing strains).</td></tr><tr><th>Pharmacodynamics</th><td>Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.</td></tr><tr><th>Mechanism of action</th><td>Like all beta-lactam antibiotics, cefixime binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefixime interferes with an autolysin inhibitor.</td></tr><tr><th>Absorption</th><td>About 40%-50% absorbed orally whether administered with or without food, however, time to maximal absorption is increased approximately 0.8 hours when administered with food.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>65% (concentration independent)</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Approximately 50% of the absorbed dose is excreted unchanged in the urine in 24 hours.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>3-4 hours (may range up to 9 hours). In severe renal impairment (5 to 20 mL/min creatinine clearance), the half-life increased to an average of 11.5 hours.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting.</td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.7776</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9704</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7432</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6934</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8863</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8724</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8301</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.9002</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8161</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9029</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7495
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8549
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9911
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.6878 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9897
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.895
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Lederle laboratories div american cyanamid co</li>
<li>Lupin pharmaceuticals inc</li>
<li>Lupin ltd</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li>Dept Health Central Pharmacy</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.lupinpharmaceuticals.com">Lupin Pharmaceuticals Inc.</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder, for suspension</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01032">Probenecid</a></td><td>Probenecid may increase the serum level of cefixime.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Preferably on an empty stomach, rate of absorption is decreased but extenet of absorption remains the same: not really problematic.</li></ul></td></tr></tbody></table>